JP MORGAN/CALL/ELI LILLY & CO/1350/0.01/20.06.25 | Real-time Bid/Ask 18:11:23 23/05/2024 BST | ||
| 0.16 EUR / 0.18 EUR | +6.25% |
|
| Current month | +6.67% | ||
| 1 month | +45.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 0.17 | +6.25% |
| 22/05/24 | 0.16 | +33.33% |
| 21/05/24 | 0.12 | +9.09% |
| 20/05/24 | 0.11 | 0.00% |
| 17/05/24 | 0.11 | -15.38% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 09:52 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK606G |
| ISIN | DE000JK606G9 |
| Date issued | 10/04/2024 |
| Strike | 1,350 $ |
| Maturity | 20/06/2025 (393 Days) |
| Parity | 100 : 1 |
| Emission price | 0.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.17 € |
|---|---|
| Lowest since issue | 0.079 € |
| Spread | 0.02 € |
| Spread % | 11.11% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.4
USD
Spread / Average Target
+5.92%
- Stock Market
- Warrants
- Warrant
